PD-L1-positivity was assessed using an archived FFPE tumor sample or a newly obtained core or excisional biopsy sample and defined as membranous staining on ≥1% in a modified proportion score or interface pattern as assessed using a laboratory-developed prototype IHC assay with the 22C3 antibody (combined positive score [CPS]). The gene discussed is CD274; the disease is neoplasm.